Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dextrose monohydrate + sodium chloride + potassium acetate is a **multi-electrolyte intravenous fluid combination** intended for parenteral maintenance of routine daily fluid and electrolyte requirements while providing a small amount of carbohydrate calories from dextrose. Pharmacologically, this is not a receptor-targeted therapy; its therapeutic effect comes from supplying **water, glucose, sodium, chloride, potassium, and acetate ions** to help maintain intravascular and extracellular fluid balance, support electrolyte homeostasis, and provide limited caloric support. Based on the provided context, the exact three-component name appears to refer to a **nonproprietary component-level description** rather than a uniquely marketed drug product, and the closest identified commercial analogue is a broader electrolyte formulation such as Normosol-M and 5% Dextrose Injection, which also contains magnesium acetate. Accordingly, this entry is best treated as a specific electrolyte combination concept rather than a clearly validated standalone branded product.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dextrose monohydrate + sodium chloride + potassium acetate.